Advisory Panel Urges Randomized Trials For New Prostate Cancer Treatments
This article was originally published in The Gray Sheet
Executive Summary
Developers of targeted prostate cancer treatments should conduct randomized clinical trials with "watchful waiting" as a control, according to FDA's Gastroenterology and Urology Devices panel
You may also be interested in...
Prostate Cancer Trials Face Randomization Challenges In U.S.
Device marketing, patient preferences, physician bias and financial incentives can thwart attempts by comparative effectiveness researchers to randomize prostate cancer patients into clinical trials.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.